Clinician reference · Geriatric outpatient
Special tests, cutoffs, and the dose that actually works.
The evidence base underneath the fallrisks.com screener, laid out for the clinician doing the evaluation. Fall risk, strength, endurance, and frailty measures with their published thresholds — then the dosing parameters that separate a program that reduces falls from one that merely happens.
Use this as a reference, not a protocol. Cutoffs are screening thresholds drawn from
specific study populations and vary by age, sex, and setting. No single measure is sufficient on its
own — the sections below flag where that matters most. Clinical judgment governs.
01 · Fall risk & balance
Balance and fall-risk measures
Fast, clinic-friendly discriminators. Pair at least two.
| Test | Cutoff | What it detects |
|---|---|---|
| 30-Second Chair Stand | <8 reps | Fall risk plus a lower-extremity strength/power proxy. Age- and sex-specific norms (Rikli & Jones). Fast, and fits inside a standard functional battery. |
| Timed Up and Go (TUG) | >13.5 sec | Widely used, but modest sensitivity and specificity in isolation (Barry et al. meta-analysis). Treat as one input, never the determinant. |
| 4-Stage Balance (CDC STEADI) | Tandem stance <10 sec | Fast, free, and a strong discriminator for fall risk. Requires no equipment. |
| Berg Balance Scale | <45/56 | More sensitive to change over time than TUG — the better choice for documenting progress across a plan of care. |
| Functional Gait Assessment | <22/30 | Outperforms DGI for vestibular- and balance-specific deficits. Useful where dizziness or BPPV overlaps the picture. |
| 5× Sit-to-Stand | >12 sec | Overlaps the 30-second chair stand; the better option when a patient can’t tolerate the full 30 seconds (Whitney et al.). |
TUG alone is not enough. Its sensitivity and specificity as a solo screen are modest. Combine it with a second balance measure before drawing a conclusion about fall risk.
02 · Strength
Strength and sarcopenia measures
| Test | Cutoff | What it detects |
|---|---|---|
| 30-Second Chair Stand | <8 reps | The most clinic-friendly lower-extremity strength proxy available (Rikli & Jones norms). |
| Grip Strength (dynamometry) | <27 kg men · <16 kg women | EWGSOP2 sarcopenia screen. Correlates with frailty and predicts hospitalization and mortality. |
| Manual Muscle Testing | 0–5 scale | Standard grading, but subject to ceiling effects in ambulatory older adults. |
MMT ceilings out. In ambulatory, higher-functioning older adults a 5/5 grade tells you very little. Favor the functional strength measures above for this population.
03 · Endurance
Aerobic capacity
| Test | Reference | What it detects |
|---|---|---|
| 6-Minute Walk Test | vs. age/sex norms | The gold standard. Distance plus heart-rate and SpO2 response; predicts hospitalization and mortality in frail elderly. |
| 2-Minute Step Test | r ≈ 0.7–0.8 vs 6MWT | A good substitute when you lack the corridor space for a 6MWT. Normative data by age and sex (Rikli & Jones). |
| 2-Minute Walk Test | — | Alternative for lower-endurance or more impaired patients where six minutes isn’t feasible. |
04 · Frailty & composite
The two measures worth putting in every evaluation
| Test | Cutoff | What it detects |
|---|---|---|
| Short Physical Performance Battery | ≤6 of 12 = high risk | Combines gait speed, chair stand, and balance. Strong predictive validity for disability and mortality, and well recognized in the Medicare and geriatric literature. |
| Gait Speed (alone) | <0.8 m/s | The most replicated single predictor of hospitalization, mortality, and disability. Cheap and fast enough that there is no good reason to omit it. |
These two carry weight in documentation. SPPB and gait speed are well recognized in the
Medicare and geriatric literature, which makes them useful to cite directly when justifying the medical
necessity of skilled therapy — the same measures that predict the outcome also support the claim.
05 · Dosing
The measure the batteries cannot capture
Standardised batteries have norms but no idea what matters to this patient. The Patient-Specific Functional Scale is the inverse, which is why it pairs with them rather than replacing either.
The patient names 3–5 activities their condition limits — getting off the toilet, walking to the
mailbox, carrying laundry upstairs — and rates each 0 (unable) to 10 (pre-onset). The score is the average.
Administration takes 3–5 minutes. MCID is about 2 points, and the comparison is only
valid if reassessment uses the same patient-selected activities.
Use it alongside the objective batteries, never instead of them: PSFS has no population norms, and
SPPB and gait speed have no individual relevance. Each covers the other's blind spot — and a
documented change in an activity the patient chose is harder to dismiss than a change in a score they
never cared about.
Stratford et al. 1995; validated in geriatric orthopaedic and neurologic populations.
What dose actually reduces falls
Measuring risk is the easy half. These are the program parameters with fall-reduction evidence behind them — and the thresholds below which the effect largely disappears.
Otago Exercise Programme
Strength 3×/week (5 LE exercises, progressive ankle cuff weights from ~0.5 kg, ~10 reps, 1–2 sets).
Balance 3×/week (12 progressive exercises). Walking 2×/week, ~30 min.
Delivered and progressed by a PT at weeks 1, 4, 8, then monthly.
~35% reduction in falls and fall-related injuries
(Robertson et al. 2001; Campbell & Robertson 2003). Minimum 12 months for full effect;
best evidence in adults 80+ or with a fall history.
LiFE — Lifestyle Integrated Functional Exercise
Balance and strength embedded into daily routines rather than a scheduled exercise block —
one-leg stand while brushing teeth, sit-to-stand before answering the phone. Roughly 7 PT visits
over 6 months, then self-managed on principle-based training.
Comparable fall reduction to structured Otago-style programs
at 12 months (Clemson et al. 2012). Best fit where adherence to a formal HEP is poor —
habit cueing outlasts a checklist.
Progressive Resistance Training
60–80% 1RM as a reference range, but dose by effort, not percentage —
train to roughly 2–3 reps in reserve. Training near failure is sufficient; absolute failure is not
required, and formal 1RM testing can be skipped entirely in frail or fall-risk patients.
2–3 sets, 2×/week minimum across major muscle groups.
No modality is superior — bands and bodyweight are legitimate primary tools, not equipment-limited
substitutes. Progress load ~2–5% once the patient beats the target effort with good form.
Never progress load and volume simultaneously.
ACSM Position Stand, Med Sci Sports Exerc 2026;58(4):851–872 — 137 systematic
reviews, first update in 17 years, supersedes the 2009 progression-models stand.
Scoped to healthy adults; for frailty use the card beside this one.
Resistance training with frailty
3×/week. Start at 20–30% 1RM and progress to 80% over a longer,
more closely monitored timeline than the general older-adult protocol. Begin at 1 set, progress to 3 sets of
8–12 reps. Rest ~2 minutes between sets — longer than younger populations need.
Add power work (higher-velocity concentric at 40–60% 1RM) once base strength exists —
power predicts function and fall risk better than strength alone, and it is the component most often skipped.
But defer high-velocity work until form is established; poor execution and severe OA are contraindications.
Extra caution at shoulder, hip, knee and spine.
Fragala et al., NSCA Position Statement, J Strength Cond Res 2019;33(8):2019–2052.
Marked gains are documented even in institutionalised nonagenarians.
Balance dose-response — the thresholds
3×/week minimum — 2×/week shows meaningfully smaller effect sizes.
≥50 hours cumulative — total exposure matters more than any single session length; programs under this threshold show weaker fall reduction.
Challenge calibrated — reduced base of support, minimal upper-extremity support, controlled weight shifting. Target “somewhat difficult, not mastered.”
≥50 hours cumulative — total exposure matters more than any single session length; programs under this threshold show weaker fall reduction.
Challenge calibrated — reduced base of support, minimal upper-extremity support, controlled weight shifting. Target “somewhat difficult, not mastered.”
Challenge level correlates with effect size more than exercise type does, and benefit
attenuates after the program stops — so discharge planning has to include a maintenance HEP
(Sherrington et al. 2017/2019; Cochrane falls prevention review).
This is the part most programs get wrong. Sherrington’s dose-response work is the
strongest available evidence linking specific parameters — frequency, cumulative hours, and
difficulty — to actual fall reduction. It is also the most defensible anchor available when
justifying plan-of-care frequency and duration. A program at 2×/week, well under 50 cumulative hours,
at a comfortable difficulty, is not a smaller version of the evidence-based program. It is a different
intervention with a weaker effect.
Related
Which guideline applies — and the arithmetic nobody does
The dosing literature looks contradictory. It is not. Each authority answers a different question, and reading them as competing recommendations is how programmes end up well-dosed for the wrong outcome.
| If the goal is… | The authority is | And the dose is |
|---|---|---|
| Fewer falls | Sherrington / Otago | Challenging balance, 3×/week, ≥50 cumulative hours, ongoing. Challenge level drives effect size more than exercise selection does. |
| More strength, or reversing sarcopenia | ACSM 2026 / NSCA 2019 | 2–3×/week, effort-based (~2–3 reps in reserve). Use NSCA where there is frailty — the ACSM stand is scoped to healthy adults. |
| Both — the usual geriatric caseload | Otago is the integration | Strength 3×/week + balance 3×/week + walking 2×/week, held for 12 months. It is not a strength programme with balance added; both run at full dose. |
Strength training alone does not reduce falls.
This is the most commonly missed implication in the whole evidence base. A well-constructed resistance
programme raises strength, and strength is worth raising — but the fall-reduction signal in the trials
tracks balance challenge, not load. A programme that is all strength and no destabilising
balance work is dosed correctly for a different outcome than the one being documented.
The 50-hour problem
Fall reduction requires roughly 50 cumulative hours of challenging balance work.
Run the arithmetic against a typical outpatient episode: 2×/week for 8 weeks is 16 visits, and even
crediting a generous 20 minutes of genuine balance challenge per visit — the rest is assessment,
strength, gait, education — that is about 5 hours. A tenth of the dose.
No realistic clinic schedule closes that gap, and the landmark programmes never assumed it would.
Otago is roughly 7–8 visits spread across 12 months — week 1, week 4, week 8,
then monthly. LiFE is about 7 visits over 6 months, then self-managed. Both are
low-visit, long-duration, home-based by design.
Which reframes what the visits are for. They are not where the dose is delivered. They are where
the challenge level gets calibrated, progression gets taught, and the programme gets handed off —
and then the outcome depends entirely on what happens at home for the following year,
which nobody in the clinic can see. The Cochrane review is explicit that the benefit attenuates
once the programme stops, so discharge without a maintenance plan gives back the effect.
Which turns the year after discharge into a measurement problem rather than a motivational one, and
Medicare already pays to solve it — remote therapeutic monitoring bills for exactly the thing
missing here: knowing whether the prescribed dose actually happened at home.
How the home year gets measured →
Where these measures get captured
The patient-facing screener →
Nine questions, no account. What patients and families complete before they reach you.
Walk test →
The at-home functional walk, structured so the result maps onto the measures above.
Gait speed on-device →
healthgait.com measures the <0.8 m/s threshold directly — the single most predictive metric here.
Programs & resources →
STEADI materials, home modification, and where to send patients next.
Sources
Rikli & Jones (Senior Fitness Test norms) · Shumway-Cook et al. 2000 (TUG cutoff) · Barry et al. 2014 (TUG meta-analysis) · Whitney et al. (5× Sit-to-Stand) · EWGSOP2 2019 (sarcopenia grip strength cutoffs) · CDC STEADI toolkit · Robertson et al. 2001 and Campbell & Robertson 2003 (Otago) · Clemson et al. 2012 (LiFE) · Sherrington et al. 2017/2019 (balance dose-response; Cochrane falls prevention review) · ACSM/AGS position stands (PRT dosing).
This page is a clinical reference for licensed clinicians. It is not a diagnosis, not a plan of care, and not a substitute for clinical judgment or current practice guidelines. Thresholds are drawn from the cited literature and vary by population and setting.